Urolithins impair cell proliferation, arrest the cell cycle and induce apoptosis in UMUC3 bladder cancer cells

  • Joana Liberal
  • Anália Carmo
  • Célia Gomes
  • Maria Teresa Cruz
  • Maria Teresa Batista
PRECLINICAL STUDIES

Summary

Ellagitannins have been gaining attention as potential anticancer molecules. However, the low bioavailability of ellagitannins and their extensive metabolization in the gastrointestinal tract into ellagic acid and urolithins suggest that the health benefits of consuming ellagitannins rely on the direct effects of their metabolites. Recently, chemopreventive and chemotherapeutic activities were ascribed to urolithins. Nonetheless, there is still a need to screen and evaluate the selectivity of these molecules and to elucidate their cellular mechanisms of action. Therefore, this work focused on the antiproliferative effects of urolithins A, B and C and ellagic acid on different human tumor cell lines. The evaluation of cell viability and the determination of the half-maximal inhibitory concentrations indicated that the sensitivity to the studied urolithins varied markedly between the different cell lines, with the bladder cancer cells (UMUC3) being the most susceptible. In UMUC3 cells, urolithin A was the most active molecule, promoting cell cycle arrest at the G2/M checkpoint, increasing apoptotic cell death and inhibiting PI3K/Akt and MAPK signaling. Overall, the present study emphasizes the chemopreventive/chemotherapeutic potential of urolithins, highlighting the stronger effects of urolithin A and its potential to target transitional bladder cancer cells.

Keywords

Apoptosis Cell cycle Ellagitannins Intracellular signaling pathways UMUC3 Urolithins 

References

  1. 1.
    Niemetz R, Gross GG (2005) Enzymology of gallotannin and ellagitannin biosynthesis. Phytochemistry 66:2001–2011. doi:10.1016/j.phytochem.2005.01.009 CrossRefPubMedGoogle Scholar
  2. 2.
    Ascacio-Valdes JA, Buenrostro-Figueroa JJ, Aguilera-Carbo A et al (2011) Ellagitannins: biosynthesis, biodegradation and biological properties. J Med Plants Res 5:4696–4703Google Scholar
  3. 3.
    Liberal J, Costa G, Carmo A et al (2015) Chemical characterization and cytotoxic potential of an ellagitannin-enriched fraction from Fragaria vesca leaves. Arab J Chem. doi:10.1016/j.arabjc.2015.11.014
  4. 4.
    Whitley AC, Sweet DH, Walle T (2006) Site-specific accumulation of the cancer preventive dietary polyphenol ellagic acid in epithelial cells of the aerodigestive tract. J Pharm Pharmacol 58:1201–1209. doi:10.1211/jpp.58.9.0006 CrossRefPubMedGoogle Scholar
  5. 5.
    Seeram NP, Lee R, Heber D (2004) Bioavailability of ellagic acid in human plasma after consumption of ellagitannins from pomegranate (Punica granatum L.) juice. Clin Chim Acta 348:63–68. doi:10.1016/j.cccn.2004.04.029 CrossRefPubMedGoogle Scholar
  6. 6.
    Espín JC, González-Barrio R, Cerdá B et al (2007) Iberian pig as a model to clarify obscure points in the bioavailability and metabolism of ellagitannins in humans. J Agric Food Chem 55:10476–10485. doi:10.1021/jf0723864 CrossRefPubMedGoogle Scholar
  7. 7.
    Cerdá B, Espín JC, Parra S et al (2004) The potent in vitro antioxidant ellagitannins from pomegranate juice are metabolised into bioavailable but poor antioxidant hydroxy-6H-dibenzopyran-6-one derivatives by the colonic microflora of healthy humans. Eur J Nutr 43:205–220. doi:10.1007/s00394-004-0461-7 CrossRefPubMedGoogle Scholar
  8. 8.
    Selma MV, Beltrán D, García-Villalba R et al (2014) Description of urolithin production capacity from ellagic acid of two human intestinal Gordonibacter species. Food Funct 5:1779–1784. doi:10.1039/c4fo00092g CrossRefPubMedGoogle Scholar
  9. 9.
    Larrosa M, González-Sarrías A, Yáñez-Gascón MJ et al (2010) Anti-inflammatory properties of a pomegranate extract and its metabolite urolithin-a in a colitis rat model and the effect of colon inflammation on phenolic metabolism. J Nutr Biochem 21:717–725. doi:10.1016/j.jnutbio.2009.04.012 CrossRefPubMedGoogle Scholar
  10. 10.
    Seeram NP, Zhang Y, McKeever R et al (2008) Pomegranate juice and extracts provide similar levels of plasma and urinary ellagitannin metabolites in human subjects. J Med Food 11:390–394. doi:10.1089/jmf.2007.650 CrossRefPubMedPubMedCentralGoogle Scholar
  11. 11.
    González-Sarrías A, Giménez-Bastida JA, García-Conesa MT et al (2010) Occurrence of urolithins, gut microbiota ellagic acid metabolites and proliferation markers expression response in the human prostate gland upon consumption of walnuts and pomegranate juice. Mol Nutr Food Res 54:311–322. doi:10.1002/mnfr.200900152 CrossRefPubMedGoogle Scholar
  12. 12.
    Nuñez-Sánchez MA, García-Villalba R, Monedero-Saiz T et al (2014) Targeted metabolic profiling of pomegranate polyphenols and urolithins in plasma, urine and colon tissues from colorectal cancer patients. Mol Nutr Food Res 58:1199–1211. doi:10.1002/mnfr.201300931 CrossRefPubMedGoogle Scholar
  13. 13.
    González-Barrio R, Borges G, Mullen W, Crozier A (2010) Bioavailability of anthocyanins and ellagitannins following consumption of raspberries by healthy humans and subjects with an ileostomy. J Agric Food Chem 58:3933–3939. doi:10.1021/jf100315d CrossRefPubMedGoogle Scholar
  14. 14.
    Bialonska D, Ramnani P, Kasimsetty SG et al (2010) The influence of pomegranate by-product and punicalagins on selected groups of human intestinal microbiota. Int J Food Microbiol 140:175–182. doi:10.1016/j.ijfoodmicro.2010.03.038 CrossRefPubMedGoogle Scholar
  15. 15.
    González-Barrio R, Truchado P, Ito H et al (2011) UV and MS identification of Urolithins and Nasutins, the bioavailable metabolites of ellagitannins and ellagic acid in different mammals. J Agric Food Chem 59:1152–1162. doi:10.1021/jf103894m CrossRefPubMedGoogle Scholar
  16. 16.
    Seeram NP, Henning SM, Zhang Y et al (2006) Pomegranate juice ellagitannin metabolites are present in human plasma and some persist in urine for up to 48 hours. J Nutr 136:2481–2485PubMedGoogle Scholar
  17. 17.
    Ishimoto H, Shibata M, Myojin Y et al (2011) In vivo anti-inflammatory and antioxidant properties of ellagitannin metabolite urolithin a. Bioorg Med Chem Lett 21:5901–5904. doi:10.1016/j.bmcl.2011.07.086 CrossRefPubMedGoogle Scholar
  18. 18.
    Larrosa M, González-Sarrías A, García-Conesa MT et al (2006) Urolithins, ellagic acid-derived metabolites produced by human colonic microflora, exhibit estrogenic and antiestrogenic activities. J Agric Food Chem 54:1611–1620. doi:10.1021/jf0527403 CrossRefPubMedGoogle Scholar
  19. 19.
    Qiu Z, Zhou B, Jin L et al (2013) In vitro antioxidant and antiproliferative effects of ellagic acid and its colonic metabolite, urolithins, on human bladder cancer T24 cells. Food Chem Toxicol 59:428–437. doi:10.1016/j.fct.2013.06.025 CrossRefPubMedGoogle Scholar
  20. 20.
    Vicinanza R, Zhang Y, Henning SM, Heber D (2013) Pomegranate juice metabolites, Ellagic acid and Urolithin a, synergistically inhibit androgen-independent prostate cancer cell growth via distinct effects on cell cycle control and apoptosis. Evid Based Complement Alternat Med 2013:247504. doi:10.1155/2013/247504 CrossRefPubMedPubMedCentralGoogle Scholar
  21. 21.
    Kasimsetty SG, Bialonska D, Reddy MK et al (2009) Effects of pomegranate chemical constituents/intestinal microbial metabolites on CYP1B1 in 22Rv1 prostate cancer cells. J Agric Food Chem 57:10636–10644. doi:10.1021/jf902716r CrossRefPubMedGoogle Scholar
  22. 22.
    Seeram NP, Aronson WJ, Zhang Y et al (2007) Pomegranate ellagitannin-derived metabolites inhibit prostate cancer growth and localize to the mouse prostate gland. J Agric Food Chem 55:7732–7737. doi:10.1021/jf071303g CrossRefPubMedGoogle Scholar
  23. 23.
    O’Brien J, Wilson I, Orton T, Pognan F (2000) Investigation of the Alamar blue (resazurin) fluorescent dye for the assessment of mammalian cell cytotoxicity. Eur J Biochem 267:5421–5426. doi:10.1046/j.1432-1327.2000.01606.x CrossRefPubMedGoogle Scholar
  24. 24.
    Kallio T, Kallio J, Jaakkola M et al (2013) Urolithins display both antioxidant and pro-oxidant activities depending on assay system and conditions. J Agric Food Chem 61:10720–10729. doi:10.1021/jf403208d CrossRefPubMedGoogle Scholar
  25. 25.
    Adams LS, Zhang Y, Seeram NP et al (2010) Pomegranate ellagitannin-derived compounds exhibit antiproliferative and antiaromatase activity in breast cancer cells in vitro. Cancer Prev Res (Phila) 3:108–113. doi:10.1158/1940-6207.CAPR-08-0225 CrossRefGoogle Scholar
  26. 26.
    Doherty SC, McKeown SR, McKelvey-Martin V et al (2003) Cell cycle checkpoint function in bladder cancer. J Natl Cancer Inst 95:1859–1868CrossRefPubMedGoogle Scholar
  27. 27.
    Cho H, Jung H, Lee H et al (2015) Chemopreventive activity of ellagitannins and their derivatives from black raspberry seeds on HT-29 colon cancer cells. Food Funct 6:1675–1683. doi:10.1039/c5fo00274e CrossRefPubMedGoogle Scholar
  28. 28.
    González-Sarrías A, Giménez-Bastida JA, Núñez-Sánchez MÁ et al (2014) Phase-II metabolism limits the antiproliferative activity of urolithins in human colon cancer cells. Eur J Nutr 53:853–864. doi:10.1007/s00394-013-0589-4 CrossRefPubMedGoogle Scholar
  29. 29.
    Kasimsetty SG, Bialonska D, Reddy MK et al (2010) Colon Cancer chemopreventive activities of pomegranate ellagitannins and urolithins. J Agric Food Chem 58:2180–2187. doi:10.1021/jf903762h CrossRefPubMedGoogle Scholar
  30. 30.
    Strober W (2001) Trypan blue exclusion test of cell viability. Curr Protoc Immunol appendix 3:appendix 3B. doi:10.1002/0471142735.ima03bs21
  31. 31.
    Stoddart MJ (2011) Cell viability assays: introduction. Methods Mol Biol 740:1–6. doi:10.1007/978-1-61779-108-6_1 CrossRefPubMedGoogle Scholar
  32. 32.
    Chang F, Lee JT, Navolanic PM et al (2003) Involvement of PI3K/Akt pathway in cell cycle progression, apoptosis, and neoplastic transformation: a target for cancer chemotherapy. Leukemia 17:590–603. doi:10.1038/sj.leu.2402824 CrossRefPubMedGoogle Scholar
  33. 33.
    Wu X, Obata T, Khan Q et al (2004) The phosphatidylinositol-3 kinase pathway regulates bladder cancer cell invasion. BJU Int 93:143–150CrossRefPubMedGoogle Scholar
  34. 34.
    Knowles MA, Platt FM, Ross RL, Hurst CD (2009) Phosphatidylinositol 3-kinase (PI3K) pathway activation in bladder cancer. Cancer Metastasis Rev 28:305–316. doi:10.1007/s10555-009-9198-3 CrossRefPubMedPubMedCentralGoogle Scholar
  35. 35.
    Wada T, Penninger JM (2004) Mitogen-activated protein kinases in apoptosis regulation. Oncogene 23:2838–2849. doi:10.1038/sj.onc.1207556 CrossRefPubMedGoogle Scholar
  36. 36.
    Knowles MA, Hurst CD (2014) Molecular biology of bladder cancer: new insights into pathogenesis and clinical diversity. Nat Rev Cancer 15:25–41. doi:10.1038/nrc3817 CrossRefGoogle Scholar
  37. 37.
    González-Sarrías A, Espín J-C, Tomás-Barberán FA, García-Conesa M-T (2009) Gene expression, cell cycle arrest and MAPK signalling regulation in Caco-2 cells exposed to ellagic acid and its metabolites, urolithins. Mol Nutr Food Res 53:686–698. doi:10.1002/mnfr.200800150 CrossRefPubMedGoogle Scholar
  38. 38.
    González-Sarrías A, Tomé-Carneiro J, Bellesia A et al (2015) The ellagic acid-derived gut microbiota metabolite, urolithin a, potentiates the anticancer effects of 5-fluorouracil chemotherapy on human colon cancer cells. Food Funct 6:1460–1469. doi:10.1039/c5fo00120j CrossRefPubMedGoogle Scholar
  39. 39.
    Sánchez-González C, Ciudad CJ, Izquierdo-Pulido M, Noé V (2015) Urolithin a causes p21 up-regulation in prostate cancer cells. Eur J Nutr. doi:10.1007/s00394-015-0924-z
  40. 40.
    Truchado P, Larrosa M, García-Conesa MT et al (2012) Strawberry processing does not affect the production and urinary excretion of urolithins, ellagic acid metabolites, in humans. J Agric Food Chem 60:5749–5754. doi:10.1021/jf203641r CrossRefPubMedGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC 2017

Authors and Affiliations

  1. 1.Escola Superior de Saúde Dr. Lopes DiasInstituto Politécnico de Castelo BrancoCastelo BrancoPortugal
  2. 2.CNC.IBILIUniversity of CoimbraCoimbraPortugal
  3. 3.Serviço de Patologia ClinicaCentro Hospitalar e Universitário de CoimbraCoimbraPortugal
  4. 4.Laboratory of Pharmacology and Experimental Therapeutics, Institute for Biomedical Imaging and Life Sciences (IBILI), Faculty of MedicineUniversity of CoimbraCoimbraPortugal
  5. 5.Center of Investigation in Environment, Genetics and Oncobiology (CIMAGO), Faculty of MedicineUniversity of CoimbraCoimbraPortugal
  6. 6.Faculty of PharmacyUniversity of CoimbraCoimbraPortugal

Personalised recommendations